Conatus Pharmaceuticals

^{Priced, Nasdaq: CNAT}

Biotech in Phase 2 trials developing treatments for chronic liver disease.

Industry: Health Care

First Day Return: -13.6%

CNAT

Biotech in Phase 2 trials developing treatments for chronic liver disease.

IPO News for Conatus Pharmaceuticals

Liver disease biotech Vital Therapies revives IPO filing, removes original terms 03/11/14
US IPO Recap: 11 deals price in busiest week since November 2007, eight companies set terms 07/26/13
Conatus Pharmaceuticals prices upsized IPO at $11 midpoint 07/25/13

IPO Data
IPO Date	07/24/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$66
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.conatuspharma.com
Headquarters	San Diego, CA, United States
Founded	2005
Employees at IPO	15

IPO News for Conatus Pharmaceuticals

Conatus Pharmaceuticals (CNAT) Performance